Medication info
Olmefoss Tablet 5/20 Milligrams (Amlodipine Besylate, Olmesartan Medoxomil)

Olmefoss Tablet 5/20 Milligrams (Amlodipine Besylate, Olmesartan Medoxomil)

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›20mg / 1 tablet
Manufacturer / importer
JW Pharmaceutical Corporation
Appearance
White round film-coated tablet
Packaging
28 tablets (14 tablets/PTP x 2)
Approval status
Active

MFDS item code 201404593 · Approved 2014.10.06 · Insurance code 644913840

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
Administer 1 tablet once daily with water, regardless of meals. It is recommended to take this medicine at the same time each day (e.g., in the morning), if possible. Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood-pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Do not administer to the following patients under Precautions for Use.) ∘Elderly patients: Treatment is generally initiated at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
Child dose
The safety and efficacy have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
JW Pharmaceutical Corporation

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

This medication is used in patients with essential hypertension who have difficulty controlling blood pressure with monotherapy of Amlodipine or Olmesartan Medoxomil, aiming to effectively manage blood pressure.

How to take

Adult dose

Administer 1 tablet once daily with water, regardless of meals. It is recommended to take this medicine at the same time each day (e.g., in the morning), if possible. Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood-pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Do not administer to the following patients under Precautions for Use.) ∘Elderly patients: Treatment is generally initiated at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.

Child dose

The safety and efficacy have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the 2nd and 3rd trimester of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients with an allergy to any of the components, those who are pregnant or breastfeeding, those with severe liver disease, specific heart and kidney diseases, and certain diabetes patients should not take this medication. Caution is advised for hypotensive patients with a deficit of fluids or salt, as blood pressure may drop too low during initial dosing, necessitating careful monitoring of their condition. If hypotension occurs, appropriate action must be taken. Patients with aortic stenosis or severe heart disease should be closely monitored since rapid vasodilation may lead to hypotension. Patients with kidney disease or impaired kidney function should consult their healthcare provider before taking this medication, as it may impact kidney function. Patients with poor liver function should also use this medication with caution. Side effects such as dizziness, headache, low blood pressure, dyspepsia, and edema may occur while taking this medication, and any unusual symptoms should be reported immediately. Particularly, blood potassium levels may rise, so caution is needed when taking this medication alongside other drugs that can affect potassium levels. This medication should not be used during pregnancy, and if planning for or already pregnant, consultation with a healthcare provider is essential. While breastfeeding, this medication may pass into breast milk, possibly necessitating the cessation of breastfeeding or the medication itself. Safety and efficacy have not been established for children under 18 years of age, so it is not recommended. Elderly patients may require dosage adjustments due to decreased kidney and liver function affecting the drug's efficacy. Overdose may lead to significantly lowered blood pressure and rapid heart rate, necessitating immediate medical assistance. This medication should be stored in a closed container away from moisture and heat, and out of reach of children.

Side effects

Drug hypersensitivity, hyperkalemia, decreased libido, dizziness, headache, orthostatic hypotension, drowsiness, paresthesia, sensory loss, syncope, vertigo, palpitations, rapid heartbeat, hypotension, orthostatic hypotension, dyspnea, cough, nausea, vomiting, dyspepsia, diarrhea, constipation, dry mouth, abdominal pain, rash, urticaria, muscle tension, limb pain, low back pain, frequent urination, erectile dysfunction, peripheral edema, edema, pitting edema, fatigue, asthenia, facial edema, decreased serum potassium, increased serum creatinine, increased serum uric acid, increased gamma-glutamyl transferase, decreased hemoglobin and hematocrit, cholelithiasis, male breast neoplasm, exacerbation of cerebral infarction, gum bleeding, orthostatic dizziness, chest pain, cold, increased CRP, fever, hemoptysis, excessive sneezing, runny nose, laryngitis, arthritis, flank pain, generalized pain, hypoglycemia, weight loss, heartburn, gastroenteritis, herpes zoster, diplopia, insomnia, asthenia, angioedema, chronic malabsorption syndrome - similar intestinal disease, bowel vascular edema, rhabdomyolysis, acute kidney failure, increased serum creatinine, hair loss, itching, autoimmune hepatitis, hyperkalemia, flushing, fatigue, edema, palpitations, dizziness, headache, drowsiness, abdominal pain, nausea, gynecomastia, jaundice, increased liver enzymes, leukopenia, thrombocytopenia, toxic epidermal necrolysis, hypotension, tachycardia, non-cardiogenic pulmonary edema, bradycardia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. It is recommended to maintain the storage temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

White round film-coated tablet

Package unit

28 tablets (14 tablets/PTP x 2)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.